Septerna, Inc. Common Stock

Septerna, Inc. is a clinical-stage biotechnology company that discovers and develops oral small molecule products targeting G protein-coupled receptors (GPCRs) for endocrinology, immunology and inflammation, and metabolic diseases. Its programs include PTH1R agonists for hypoparathyroidism, SEP-631 (an MRGPRX2 negative allosteric modulator) for chronic spontaneous urticaria and other mast cell diseases, and TSHR negative allosteric modulators for Graves' disease and thyroid eye disease. It also focuses on neurology, women's health, cardiovascular disease, and respiratory disease. The company has a global collaboration and license agreement with Novo Nordisk to discover, develop, and commercialize multiple potential oral small molecule therapies for metabolic-related diseases based on specified molecular targets. Formerly known as GPCR NewCo, Inc., it changed its name to Septerna Inc. in June 2021, was incorporated in 2019, and is headquartered in South San Francisco, California.

Biotech & Genomic Medicine▲

Septerna's SEP-479 Preclinical Data Accepted for ENDO 2026 Presentation

Septerna announced that the first comprehensive preclinical characterization of its oral hypoparathyroidism candidate SEP-479 has been accepted for an oral presentation at the 2026 Endocrine Society's Annual Meeting. The presentation will cover the pharmacological profile of SEP-479, a selective small-molecule PTH1R agonist, with preclinical studies showing strong activity in laboratory and animal models. SEP-479 is currently in a Phase 1 trial in healthy volunteers, with initial data expected in late 2026 or early 2027. The company believes the candidate could offer a once-daily oral treatment option for hypoparathyroidism. Separately, Guggenheim initiated coverage of Septerna with a Buy rating and a $52 price target.

SEPN ▲

Biotech & Genomic Medicine

Insider Monkey·78dRead more →